An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs IONIS HTTRx (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 07 Jun 2019 Planned number of patients changed from 900 to 950.
- 01 Apr 2019 Status changed from not yet recruiting to recruiting.
- 14 Feb 2019 Status changed from planning to not yet recruiting.